Business Parks & Science Centres



Picture Kentro Design Corporate and Web Design Berlin 600x60px
Financing › Details

JenaValve–SEVERAL: investment, 201003 financing round Series B €19m led by new investors VI Partners + Sunstone Capital


Period Period 2010-03-29
  Predecessor JenaValve–SEVERAL: investment, 200709 financing round Series A-2 €10m led by EdRIP + incl Atlas Venture + NeoMed
  Successor JenaValve–SEVERAL: investment, 201307 financing round Series C $62.5m led by Gimv
Organisation Money taker JenaValve Technology GmbH
Products Product TAVI system (transcatheter arotic valve implantation system)
  Product 2 venture capital

JenaValve Technology, Inc.. (3/29/10). "Press Release: JenaValve Closes € 19 Million Series B Financing Round". Delaware & Munich.

JenaValve™ Technology, Inc., a medical device company specialized in developing transcatheter valve implantation systems (TAVI), today announced that it has closed on a €19 million Series B round led by two co-lead-investors, VI Partners AG, Switzerland and Sunstone Capital A/S, Denmark. Gimv NV, Belgium, joined the consortium as co-investor.

Commenting on the announcement, JenaValve's CEO Helmut J. Straubinger said, "We are very pleased that our value proposition resonated so strongly with the financial community. Potential investors showed interest and funding possibilities far in excess of our expectation." He continued, "This investment ensures the company's financing for our transapical and transfemoral systems up until our European market entry."

CFO Stephan Wehselau said, "The Series B round proved to be very cooperative thanks to the professionalism of the three new investors. Our original investors firmly believe in our products and are 100 percent behind us - they have increased their financial participation quite significantly."

"The TAVI market was very high on our list of investment goals. JenaValve has the proof points to make it a winner on an international scale. We are delighted to be working with the company and the other investors to build a leading company in this exciting area," said Arnd Kaltofen, General Partner at VI Partners.

Existing investors include Edmond de Rothschild Investment Partners (EdRIP), France, NeoMed Management, Norway and founding investor Atlas Venture, USA/UK.

Arnd Kaltofen joins existing board members Helmut J. Straubinger, Michael J. Dormer, Markus Ferrari, Regina Hodits (Atlas Venture) and Olivier Litzka (EdRIP). Christian Gilhuus-Moe (NeoMed) now also joins the board as a full member.

Trine Bartholdy (Sunstone Capital) as well as Patrick Van Beneden (Gimv), will become observers to the board.

About JenaValve Technology

JenaValve Technology is a medical device company focused on developing transcatheter-delivered aortic
valve systems to treat patients with aortic valve disease. The company has aortic valve delivery systems for
both transapical and transfemoral approaches to address the needs of both the cardiac surgeon and
cardiologist, respectively.

JenaValve's systems feature the unique JenaClipTM stented aortic valve that provides accurate placement
and the ability to retract and reposition the device if needed for enhanced patient safety. Precise placement
reduces the potential for complications such as coronary blockage, paravalvular leakage and heart block.
The company's products are currently targeted for high-risk patients unsuitable for traditional open heart
surgery. The JenaValve Transapical System is currently under clinical investigation in Germany.

JenaValve Technology GmbH is headquartered in Munich, Germany; its holding company is JenaValve
Technology, Inc., Delaware, USA. Additional company information is available at
JenaValve and JenaClip are trademarks of JenaValve Technology GmbH. The JenaValve products are
protected by pending and granted patent, design and utility model rights.


All information contained in this document derives from plausible reliable sources, which, however, have not
been independently examined. There is no warranty, confirmation or guarantee and no responsibility or
liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no
liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this document or
its contents. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible.
International investors acknowledge risks in connection with political and economic uncertainties in foreign
countries as well as currency risks. Persons who are in possession of this document are requested to obtain
information concerning possible legal limitations and to observe them accordingly.

Press contacts:
Lucy Turpin Communications GmbH
Brigitte Wenske, PR & MarCom Manager
Tel. +49 (0)89 417761-42

Record changed: 2017-04-02


Picture [LSUS] – The Business Web Portal 600x60px

More documents for JenaValve Technology GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [LSUS] – The Business Web Portal 600x60px

» top